ResearchPUBMEDMar 26
A study in Indonesia looked at how doctors and patients used video visits (telemedicine) to manage long-term and rare diseases during COVID-19. The research found that telemedicine helped people get care when hospitals were hard to reach, but there are challenges like internet problems and cost that need to be fixed for it to keep working after the pandemic ends.
WHY IT MATTERSIf you have a rare disease in Indonesia or a similar region with limited specialist access, this research shows telemedicine could help you see doctors without traveling long distances — but you should know about potential barriers like internet reliability and costs before relying on it.
ResearchPUBMEDMar 26
A study in South Korea looked at how caring for someone with a rare genetic disease affects the caregiver's life and stress levels. Researchers surveyed 159 caregivers and found that caring for these patients creates real challenges that hurt caregivers' quality of life. The study examined what factors—like the patient's condition, available treatments, and genetic counseling—make caregiving easier or harder.
WHY IT MATTERSThis research identifies specific factors that increase caregiver burden in rare genetic diseases, which could help healthcare systems in South Korea and elsewhere design better support programs and counseling services for families managing these conditions.
ResearchPUBMEDMar 26
This study looked at how long it takes to diagnose APDS, a very rare immune system disorder that affects only 1-2 people per million. Researchers interviewed patients and doctors in Austria, Germany, and Switzerland and found that people typically wait several years before getting a correct diagnosis because the disease is so uncommon and looks different in different people.
WHY IT MATTERSPatients with APDS face years of diagnostic delay due to the disease's rarity and variable symptoms — understanding these barriers could help doctors recognize APDS faster and reduce the time families spend seeking answers.
ResearchPUBMEDMar 26
Researchers studied how cancer tumors respond differently to a two-drug immunotherapy treatment (ipilimumab plus nivolumab) in patients with rare cancers. Some patients had some tumors shrink while others grew at the same time—called 'mixed response.' This study looked at 438 patients to understand how this mixed response affects how long patients survive and whether the cancer comes back.
WHY IT MATTERSUnderstanding mixed response patterns helps doctors better predict which rare cancer patients will benefit most from dual checkpoint inhibitor therapy and may improve how treatment success is measured beyond just tumor size.
ResearchPUBMEDMar 26
Researchers studied how medicines for rare diseases are developed by non-industry groups like universities and charities, compared to pharmaceutical companies. Between 2000 and 2022, only about 7% of rare disease medicine projects came from these non-industry organizations. While these groups got help from regulators at similar rates as companies, very few of their medicines actually made it to patients—only six succeeded, and all had to partner with pharmaceutical companies to finish the job.
WHY IT MATTERSThis research shows that academic and charity-led rare disease drug projects face significant barriers to reaching patients, suggesting that funding and regulatory support for non-industry developers could unlock more treatment options for rare diseases that pharmaceutical companies might overlook.
ResearchPUBMEDMar 26
Researchers created DeepRare, a computer system that helps doctors diagnose rare diseases faster and more accurately. The system uses artificial intelligence to analyze patient information like symptoms, genetic test results, and medical history to suggest possible diagnoses. This could help patients avoid the long 'diagnostic odyssey' where they see many doctors over years before getting a correct diagnosis.
WHY IT MATTERSPatients with rare diseases spend an average of 5+ years seeking diagnosis with repeated misdiagnoses; DeepRare could dramatically shorten this timeline by providing doctors with AI-powered diagnostic support that integrates genetic and phenotype data.
PolicyPUBMEDMar 26
Scientists and doctors are saying that the system for developing and selling medicines for rare diseases needs improvement. New discoveries in genetics have helped create targeted treatments, but these medicines are often very expensive and hard to access. The article calls on researchers, doctors, and other groups to work together to make rare disease medicines more affordable and available to patients who need them.
WHY IT MATTERSIf you or a loved one has a rare disease, this research highlights why medicines for your condition may be expensive or hard to get — and pushes for systemic changes that could improve your access to treatment options.
ResearchPUBMEDMar 26
Researchers are developing a new way to make sure patients with Aicardi-Goutieres Syndrome (AGS) have a real voice in designing clinical trials for new treatments. AGS is a rare genetic disease that affects the brain and causes inflammation. This study creates a method to listen to what matters most to patients and families so that future drug trials measure the things that actually improve their lives.
WHY IT MATTERSAs new treatments for AGS move toward clinical trials, this research ensures that the outcomes being measured in those trials reflect what patients and families actually care about—not just what doctors think is important.
ResearchPUBMEDMar 26
Researchers tested new ways to help more diverse groups of people join rare disease genetic studies. They used strategies like having doctors refer patients, providing language support, and bringing blood tests to people's homes. About 83% of people they tried to recruit successfully joined the study, showing these methods work well.
WHY IT MATTERSIf you or your family member has a rare disease and belongs to a group that has been underrepresented in genetic research, this work means future studies are more likely to actively recruit and support your participation, potentially leading to better understanding of your condition.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new gene therapy called SGT-212 for Friedreich's ataxia, a rare disease that affects how the body moves and coordinates. This is the first time this treatment is being tested in humans. The study will enroll 10 patients and follow them for about 5 years to see if the treatment is safe and works well.
WHY IT MATTERSThis is the first human trial of SGT-212 for Friedreich's ataxia, offering eligible patients access to a potentially disease-modifying gene therapy that addresses the underlying genetic cause rather than just managing symptoms.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for 1,500 people with inherited eye diseases caused by rare genetic changes to join a study. The study has two parts: first, they'll collect genetic information and eye health data from participants, and second, they'll follow some participants over time to understand how these eye diseases progress. This international study is now accepting new participants.
WHY IT MATTERSIf you have an inherited retinal disease with a rare genetic variant, enrolling in this registry could help researchers understand your condition better and speed up development of future treatments while contributing to a global database of genetic information.
Clinical trialCLINICALTRIALSMar 26
Researchers at Emory University are testing a new combination of medicines for children whose cancer has come back or stopped responding to previous treatments. The study combines three drugs: sirolimus (which slows cell growth), celecoxib (an anti-inflammatory), and two chemotherapy drugs given in low doses. The goal is to see if this combination works better than standard treatments for solid tumors and brain cancers in children.
WHY IT MATTERSThis trial offers a potential new treatment option for children with recurrent or refractory cancers who have limited alternatives, though enrollment is currently closed.
ResearchCLINICALTRIALSMar 26
Researchers completed a study testing whether an artificial intelligence tool can help regular doctors better diagnose skin conditions. The AI was designed to reduce mistakes and unnecessary specialist referrals by giving primary care doctors better information about skin problems like melanoma, psoriasis, and other conditions. With only 9 participants, this was a small early-stage study to see if the technology works.
WHY IT MATTERSIf this AI tool works well, patients with rare skin conditions like hidradenitis suppurativa could get faster, more accurate diagnoses from their regular doctor instead of waiting for specialist appointments.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new treatment for calciphylaxis, a serious condition where calcium builds up in blood vessels and skin tissue, causing painful sores. The treatment uses special cells from amniotic fluid (the fluid around a baby during pregnancy) to see if they can help heal the damage. This is an early-stage trial with a small group of 9 patients to check if the treatment is safe and works.
WHY IT MATTERSCalciphylaxis has very few treatment options and high mortality rates — this trial offers patients with chronic kidney disease a chance to access an experimental stem cell therapy that could reduce tissue damage and improve survival.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a combination of two immunotherapy drugs in patients with four types of rare cancers: neuroendocrine tumors, biliary tract cancers, ovarian clear cell carcinoma, and tumors with high microsatellite instability. This Phase 2 trial involves 240 patients and is based on earlier research showing these cancers may respond well to this type of treatment.
WHY IT MATTERSPatients with these rare cancers now have access to a targeted immunotherapy combination that showed promise in earlier studies, potentially offering a new treatment option for cancers that historically have limited therapeutic choices.
ResearchCLINICALTRIALSMar 26
Researchers in Italy completed a registry study where they collected information from 82 patients with Angelman Syndrome. A registry is like a database that stores health information to help doctors and scientists learn more about a disease. No patients received any experimental treatment—they just shared their medical information, which is kept private and secure.
WHY IT MATTERSThis completed Italian registry provides real-world data on Angelman Syndrome patients that researchers can use to design better treatments and understand how the condition affects people over time.
Clinical trialCLINICALTRIALSMar 26
Researchers are looking for pregnant women and breastfeeding mothers who have taken or are taking a medication called odevixibat to join a safety study. The study will track the health of these women and their babies to make sure the medication is safe to use during pregnancy and while breastfeeding. About 20 people will participate, and doctors will collect information from the mothers, babies, and healthcare providers involved in their care.
WHY IT MATTERSThis surveillance program is recruiting pregnant and lactating women exposed to odevixibat to establish safety data for a medication used in rare bile acid disorders, filling a critical gap in pregnancy and lactation safety information.
ResearchCLINICALTRIALSMar 26
Researchers completed a study testing whether an AI tool called Legit.Health Plus can help doctors better diagnose rare and complicated skin conditions. The tool was tested with 15 healthcare providers to see if it could reduce the gap between what general doctors and skin specialists diagnose. This matters because conditions like Generalized Pustular Psoriasis and Hidradenitis Suppurativa can be missed or misdiagnosed, delaying proper treatment.
WHY IT MATTERSThis completed trial tested an AI diagnostic tool specifically designed to help primary care doctors accurately identify rare skin conditions like Generalized Pustular Psoriasis and Hidradenitis Suppurativa, which are often missed in non-specialist settings.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new cancer treatment called CART19 for children and young adults with specific types of blood cancer (B-ALL). The treatment uses the patient's own immune cells that are modified in a lab to fight cancer cells. This trial is looking for patients with rare, high-risk forms of this cancer, including some cases that have come back after previous treatment.
WHY IT MATTERSThis trial is actively recruiting children and young adults with hard-to-treat B-ALL subtypes (hypodiploid, t(17;19), KMT2A, and CNS relapse cases) — these patients have limited treatment options and this study offers access to an advanced cell therapy approach.
ResearchCLINICALTRIALSMar 26
Researchers in Pakistan completed a study testing whether a mindfulness program called MindUP could help orphan teenagers feel less depressed, anxious, and stressed. The program teaches techniques to calm the mind and manage difficult emotions. This study involved 61 teenagers living in orphan care institutions who often experience sadness and worry from losing their parents and living in institutional settings.
WHY IT MATTERSThis research demonstrates that mindfulness-based interventions can be effective mental health tools for vulnerable adolescent populations in resource-limited settings, potentially offering low-cost psychological support for orphaned youth.